Stephanie Davis
Stock Analyst at Barclays
(0.61)
# 4,141
Out of 5,150 analysts
95
Total ratings
32.84%
Success rate
-108.74%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Overweight | $210 → $225 | $208.45 | +7.94% | 8 | Feb 11, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $26.93 | +67.10% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $7.87 | -36.47% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $26.44 | +183.66% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.33 | -4.50% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.18 | +175.23% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.55 | +435.21% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $368.19 | -21.24% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $223.18 | -40.41% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $41.53 | +39.66% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $4.93 | -39.15% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $280.85 | -11.34% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $12.63 | +129.61% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $5.13 | +562.77% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $17.79 | +91.12% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $188.48 | +23.62% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $1.95 | +771.79% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $81.15 | -6.35% | 5 | Jun 7, 2022 |
Quest Diagnostics
Feb 11, 2026
Maintains: Overweight
Price Target: $210 → $225
Current: $208.45
Upside: +7.94%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $26.93
Upside: +67.10%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $7.87
Upside: -36.47%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $26.44
Upside: +183.66%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.33
Upside: -4.50%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.18
Upside: +175.23%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.55
Upside: +435.21%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $368.19
Upside: -21.24%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $223.18
Upside: -40.41%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $41.53
Upside: +39.66%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $4.93
Upside: -39.15%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $280.85
Upside: -11.34%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $12.63
Upside: +129.61%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $5.13
Upside: +562.77%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $17.79
Upside: +91.12%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $188.48
Upside: +23.62%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $1.95
Upside: +771.79%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $81.15
Upside: -6.35%